SUZANNE GREGG: Open Payments
NPI 1710369103 · HASTINGS, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,341 in 162 payments from 12 companies in 2025. Trend: 2023 $1,879 · 2024 $1,839 · 2025 $2,341
Food & beverage: $2,341
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 23 | $338 |
| Otsuka America Pharmaceutical, Inc. | 28 | $305 |
| ABBVIE INC. | 20 | $304 |
| E.R. Squibb & Sons, L.L.C. | 20 | $263 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $253 |
| Teva Pharmaceuticals USA, Inc. | 22 | $249 |
| Neurocrine BioSciences, Inc. | 14 | $208 |
| Axsome Therapeutics, Inc. | 6 | $173 |
| Janssen Pharmaceuticals, Inc | 11 | $143 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $52 |
Products named: ARISTADA, VRAYLAR, COBENFY, CAPLYTA, INGREZZA, REXULTI, Auvelity, AUSTEDO XR.
Industry payments across NE — which companies pay providers there.
